Renalytix AI

Company Profile

Renalytix AI had its IPO on 2020-07-17 under the ticker symbol RNLX.

The company operates in the Healthcare sector and Health Information Services industry. Renalytix AI has a staff strength of 102 employees.

Stock update

Shares of Renalytix AI opened at $2.28 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.27 - $2.4, and closed at $2.33.

This is a +4.73% increase from the previous day's closing price.

A total volume of 24,523 shares were traded at the close of the day’s session.

In the last one week, shares of Renalytix AI have slipped by -20.92%.

Renalytix AI's Key Ratios

Renalytix AI has a market cap of $145.57 million, indicating a price to book ratio of 3.5969 and a price to sales ratio of 21.2609.

In the last 12-months Renalytix AI’s revenue was $3.72 million with a gross profit of $874000 and an EBITDA of $-44985000. The EBITDA ratio measures Renalytix AI's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Renalytix AI’s operating margin was -1219.27% while its return on assets stood at -67.21% with a return of equity of -166.93%.

In Q1, Renalytix AI’s quarterly earnings growth was a positive 0% while revenue growth was a negative 10.8%.

Renalytix AI’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.34 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Renalytix AI’s profitability.

Renalytix AI stock is trading at a EV to sales ratio of 15.5038 and a EV to EBITDA ratio of -1.1425. Its price to sales ratio in the trailing 12-months stood at 21.2609.

Renalytix AI stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$39.80 million

Total Liabilities

$14.68 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Renalytix AI ended 2024 with $39.80 million in total assets and $0 in total liabilities. Its intangible assets were valued at $39.80 million while shareholder equity stood at $18.10 million.

Renalytix AI ended 2024 with $0 in deferred long-term liabilities, $14.68 million in other current liabilities, 286000.00 in common stock, $-167221000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $33.03 million and cash and short-term investments were $33.03 million. The company’s total short-term debt was $4,602,000 while long-term debt stood at $6.95 million.

Renalytix AI’s total current assets stands at $35.73 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $747000.00 compared to accounts payable of $3.20 million and inventory worth $0.

In 2024, Renalytix AI's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Renalytix AI paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$2.33

52-Week High

$4.038

52-Week Low

$1.05

Analyst Target Price

$5

Renalytix AI stock is currently trading at $2.33 per share. It touched a 52-week high of $4.038 and a 52-week low of $4.038. Analysts tracking the stock have a 12-month average target price of $5.

Its 50-day moving average was $2.96 and 200-day moving average was $2.54 The short ratio stood at 4.9 indicating a short percent outstanding of 0%.

Around 395.3% of the company’s stock are held by insiders while 799.9% are held by institutions.